Novel Gene Therapy Yields Funding Support by Glick, Jerold A.
Health Policy Newsletter 
____________________________________________________________ 
Volume 8, Number 2    May, 1995               Article 8 
____________________________________________________________ 
 
Novel Gene Therapy Yields Funding Support 
 
Jerold A. Glick, MS * 
 
*Thomas Jefferson University 
 
Copyright ©1995 by the author.  The Health Policy Newsletter is a publication of Thomas 
Jefferson University, Jefferson Medical College and the Department of Health Policy, 1015 
Walnut Street, Suite 621, Philadelphia, PA 19107. (215) 955-6969. 
 
Suggested Citation:
Glick, JS.  Novel gene therapy yields funding support..  Health Policy Newsletter 1995; 8(2): 
Article 8.  Retrieved [date] from http://jdc.jefferson.edu/hpn/vol8/iss2/8. 
Jerold A. Glick:  Novel Gene Therapy Yields Funding Support 
Health Policy Newsletter Vol. 8, Number 2 (May 1995), Article 8 
Novel Gene Therapy Yields Funding Support 
Little did Eric Kmiec, PhD, Associate Professor of Pharmacology, suspect when he 
was addressing an NIH-sponsored meeting in April, 1994 that he was auditioning to 
become the focus of a new biotechnology start-up company. In the audience at that 
meeting on emerging gene therapies was Mark Fisher of the investment banking firm 
of Alex. Brown & Sons. Mr. Fisher travels to such meetings seeking likely candidates 
for start-up opportunities. He was very interested in Dr. Kmiec's novel approach to 
gene therapy, which involves the use of a chimeric vector based on the activity of 
the Rec 2 gene product invented by Dr. Kmiec to repair defective genes. Current 
gene therapy for inherited diseases having specific gene mutations, such as sickle 
cell anemia and thalessemia, involves extraction of the patient's bone marrow, 
correction of the genome, then reintroduction of the marrow into the patient. To be 
successful, the progenitor cells introduced into the marrow must populate the body. 
Dr. Kmiec's approach is radically different, involving gene targeting and in vivo repair 
of the mutant gene which caused the diseased condition. Normal genes would then 
repopulate the body after which the body will no longer be subject to the disabilities 
caused by the defective gene. (Jefferson is the owner of the patents covering this 
invention.)  
 
Negotiations were opened among Dr. Kmiec, Mr. Fisher and Jefferson's offices of 
Technology Transfer and Research Administration, culminating in the execution of 
several research and licensing agreements. At the same time a new company, 
Kimeragen, Inc., was established, with control held by Fisher and his co-investors, 
and significant minority interests held by Dr. Kmiec and Jefferson. A funding program 
was agreed upon and the project was formally implemented September 1, 1994. 
Kimeragen, Inc., is committed to raising a minimum of $400,000 in its first year to 
support Dr. Kmiec's research, which is budgeted at $370,070 in the initial 12-month 
period and $1,160,000 for its first three years. This project is the sole venture to 
which Kimeragen, Inc. is committed.  
 
Though several pharmaceutical firms were interested in acquiring or funding Dr. 
Kmiec's project, he has found the Kimeragen approach much better for his purposes. 
Foremost, Dr. Kmiec retains full scientific control of the work. The external funding 
has enabled him to expand his laboratory and hire an additional faculty-level 
scientist and an additional technician. While continuing to develop his chimeric 
vector, Dr. Kmiec remains free to pursue other grant opportunities (he has several 
other research grants currently), and he retains full editorial control over any articles 
he may submit for publication. Finally, should the chimeric vector prove to be as 
effective on a large scale as it has been in confines of the laboratory, all parties 
involved with Kimeragen could receive substantial monetary rewards.  
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